For epidermal growth factor (EGFR) mutation‐positive advanced NSCLC, several classic clinical trials have shown that EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) significantly improve survival,9, 10 establishing the status of EGFR‐TKI as the first‐line standard therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.